Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 816 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Butyrate Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Bioequivalence Comparison of Baclofen and Chlorzoxazone Administered Individually or Concurrently

NCT05257447
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Baclofen 20 mg Tablet, Chlorzoxazone 500 mg Tablet, Baclofen 20mg tablet and Chlorzoxazone 500 mg tablet
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2023 · Synced Oct 23, 2026, 8:56 AM EDT
Terminated Phase 2 Interventional Results available

Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

NCT02594163
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma Refractory, Follicular B-cell Non-Hodgkin's Lymphoma
Interventions
Brentuximab Vedotin, Rituximab, Bendamustine
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
22
States / cities
Duarte, California • Santa Barbara, California • Torrance, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 23, 2026, 8:56 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Effect of Gabapentin on Postoperative Opioid Analgesic Use and Pain in Adolescents Undergoing Tonsillectomy

NCT05024825
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Gabapentin, hydrocodone, acetaminophen and ibuprofen
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
12 Years to 18 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2021 · Synced Oct 23, 2026, 8:56 AM EDT
Terminated Phase 1 Interventional

FT516 in Subjects With Advanced Hematologic Malignancies

NCT04023071
View directory record Official record
Conditions
Acute Myelogenous Leukemia, B-cell Lymphoma
Interventions
FT516, Rituximab, Obinutuzumab, Cyclophosphamide, Fludarabine, IL-2, Bendamustine
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • San Diego, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 23, 2026, 8:56 AM EDT
Completed Early Phase 1 Interventional

Improving Pain and Reducing Opioid Use (IPaRO) in Lumbar Spine Surgery Patients

NCT03088306
View directory record Official record
Conditions
Lumbar Spinal Stenosis, Lumbar Spinal Instability, Lumbar Spine Degeneration
Interventions
Standard analgesia use [Oxygen], Standard analgesia use [Hydromorphone], Standard analgesia use [Volatile Anesthesia], Standard analgesia use [Fentanyl], Multi-modal pain management [Acetaminophen + Gabapentin], Multi-modal pain management [Fentanyl], Multi-modal pain management [Intravenous Ketamine], Multi-modal pain management [Valium + Gabapentin]
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 23, 2026, 8:56 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

NCT05551936
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Bendamustine, Rituximab, Tazemetostat
Drug
Lead sponsor
Vaishalee Kenkre
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Chicago, Illinois • New Brunswick, New Jersey • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 23, 2026, 8:56 AM EDT
Completed Phase 3 Interventional

Gabapentin in Treating Peripheral Neuropathy in Cancer Patients Undergoing Chemotherapy

NCT00027963
View directory record Official record
Conditions
Neurotoxicity, Pain
Interventions
gabapentin, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
22
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 23, 2026, 8:56 AM EDT
Terminated Phase 2 Interventional Results available

CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

NCT04217317
View directory record Official record
Conditions
Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma, Non Hodgkin Lymphoma
Interventions
CPI 613, Bendamustine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 23, 2026, 8:56 AM EDT
Completed Phase 3 Interventional Results available

Surgical Pain After Inguinal Hernia Repair (SPAIHR)

NCT00551135
View directory record Official record
Conditions
Pain, Postoperative, Hernia, Inguinal
Interventions
Pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
17 Years to 75 Years · Male only
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
24
States / cities
Birmingham, Alabama • Glendale, California • Laguna Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 23, 2026, 8:56 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

NCT03997968
View directory record Official record
Conditions
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
Interventions
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Drug
Lead sponsor
Cyteir Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
16
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 23, 2026, 8:56 AM EDT
Terminated Phase 4 Interventional Results available

Gabapentin on Postoperative Pain Associated With Ureteroscopy and Stents Insertion

NCT03151746
View directory record Official record
Conditions
Anesthesia, Urethral Obstruction
Interventions
Placebo, Gabapentin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 23, 2026, 8:56 AM EDT
Completed Phase 3 Interventional Results available

Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)

NCT00542178
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Hypoglycemic Agents, Standard glycemia control, Intensive BP treatment, Standard BP control, Fenofibrate, Simvastatin, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
3,472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 23, 2026, 8:56 AM EDT
Completed Early Phase 1 Interventional

Baclofen Treatment of Ataxia Telangiectasia

NCT00640003
View directory record Official record
Conditions
Ataxia Telangiectasia
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Oct 23, 2026, 8:56 AM EDT
Completed Phase 1 Interventional

Bendamustine and Bevacizumab for Advanced Cancers

NCT01152203
View directory record Official record
Conditions
Advanced Cancer
Interventions
Bendamustine, Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
13 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 23, 2026, 8:56 AM EDT
Completed Phase 3 Interventional

Gabapentin in Treating Hot Flashes in Patients With Prostate Cancer

NCT00028574
View directory record Official record
Conditions
Hot Flashes, Prostate Cancer
Interventions
gabapentin, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
170
States / cities
Mobile, Alabama • Washington D.C., District of Columbia • Jacksonville, Florida + 103 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Oct 23, 2026, 8:56 AM EDT
Completed Phase 2 Interventional

A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia

NCT01594983
View directory record Official record
Conditions
Non Familial Chylocmicronemia Syndrome (Non-FCS)
Interventions
LCQ908, Fenofibrate, Fish Oil, Placebo of LCQ908, Placebo of fenofibrate, Placebo of fish oil
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Muscle Shoals, Alabama • Glendale, Arizona • Encinitas, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 23, 2026, 8:56 AM EDT
Active, not recruiting Phase 2 Interventional

A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT04115631
View directory record Official record
Conditions
Liver Lymphoma, Mantle Cell Lymphoma
Interventions
Acalabrutinib, Bendamustine, Bendamustine Hydrochloride, Cytarabine, Rituximab
Drug · Biological
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years to 70 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
504
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 358 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 8:56 AM EDT
Completed Phase 2 Interventional

Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders

NCT05064319
View directory record Official record
Conditions
Bipolar Disorder, Cannabis Use, Schizoaffective Disorder, Bipolar Type, Bipolar I Disorder, Bipolar II Disorder, Cannabis Use Disorder, Mild, Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 8:56 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma

NCT00547534
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
bortezomib, bendamustine, rituximab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Omaha, Nebraska • New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Oct 23, 2026, 8:56 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT01496365
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
DS-5565 tablet, pregabalin capsule, Placebo tablet, placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
78
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 23, 2026, 8:56 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy

NCT00640614
View directory record Official record
Conditions
Contact Dermatitis
Interventions
T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens
Biological
Lead sponsor
Allerderm
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Little Rock, Arkansas • Shawnee Mission, Kansas • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Oct 23, 2026, 8:56 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy

NCT00954187
View directory record Official record
Conditions
Postoperative Pain
Interventions
Gabapentin, pregabalin
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 23, 2026, 8:56 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Pregabalin in Treatment of Neuropathic Pain in Patients With Idiopathic Small Fiber Neuropathy

NCT02607254
View directory record Official record
Conditions
Idiopathic Small Fiber Neuropathy
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Oct 23, 2026, 8:56 AM EDT
Terminated Phase 2 Interventional Results available

Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

NCT01315873
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bendamustine, Bortezomib
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 23, 2026, 8:56 AM EDT